IRulya Q3 Loss Widens to $27.7M on Warrant Mark; $105.2M Cash Funds 12 Months
IRLA has more than doubled off its 52-week low of $15.1.
Summary
IRulya posted a $27.7 million Q3 loss, largely a $14.3 million non-cash warrant remeasurement, and ended September with $105.2 million in cash and investments — enough for at least twelve months. The company is now a pure LAM-001 play after writing off eDSP and selling its Italian unit.
Key Events · Earnings and Guidance · IRLA
-
Q3 Loss Driven by Non-Cash Warrant Mark
Net loss was $27.7 million ($2.31 per share) versus $13.4 million a year earlier; the quarter included a $14.3 million non-cash fair-value charge on liability-classified warrants, not a cash outflow.
-
Cash Runway of At Least Twelve Months
Cash, cash equivalents and investments totaled $105.2 million at September 30, 2026, which management says funds operations for at least the next twelve months.
-
Legacy eDSP Program Fully Written Off
A $67.8 million non-cash intangible impairment and a $64.3 million contingent consideration reversal followed the January 2026 Phase 3 NEAT failure; the Italian subsidiary was sold for $0.5 million cash, producing a $1.7 million gain.
-
Series C Converts; 9.8M Shares Issued
On October 9, 2026, 188,930.369 Series C Preferred shares converted into 9,824,407 common shares; 22,371.499 Series C shares remain outstanding as of November 5, 2026 due to beneficial ownership caps, and authorized common stock rose to 275,000,000.
Analysis · IRLA · Life Sciences
The headline loss looks alarming, but most of it is accounting noise: the $27.7 million quarterly loss includes a $14.3 million non-cash charge from remeasuring liability-classified warrants, not cash leaving the business. The real story is the balance sheet — $105.2 million of cash and investments after the May 2026 Orphai deal and $115 million private placement, which management says funds operations for at least twelve months. Against that, the company is now a single-asset story: LAM-001 in PH-ILD, BOS and SAPH, with the first real readout (BOS Phase 2) not expected until Q1 2027. The legacy eDSP program is fully written off ($67.8 million impairment) and the Italian subsidiary sold, so there is no revenue and no near-term catalyst beyond trial execution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRLA was trading at $39.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $431.5M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.